Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

About this update from Sight Sciences, Inc.

[{"type":"image","alt":"Sight Sciences, Inc.","displaySize":"","headline":null,"caption":"Sight Sciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/75f822c295d5666cdf692b6ef7429971"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iWYluxF6m_THbwAGSEG.kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/75f822c295d5666cdf692b6ef7429971","width":300,"height":106}},"lazy":false},{"type":"text","content":"MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.","length":461,"tagName":"p"},{"type":"text","content":"Recent Financial and Business Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company’s Surgical Glaucoma segment, which decreased 6% compared to the same period in the prior year. The expected decrease was primarily due to the new Medicare LCDs that restricted Medicare coverage for multiple MIGS procedures when performed at the same time as a cataract procedure.","length":469,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved total gross margin of 86% of revenue in the first quarter of 2025, which is equal to total gross margin in the same period in the prior year.","length":150,"tagName":"p"}]},{"val":[{"type":"text","content":"Reduced total operating expenses to $29.0 million in the first quarter of 2025, representing a 7% decrease compared to $31.2 million in the same period in the prior year.","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Launched OMNI Edge at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in April. OMNI Edge with TruSync™ technology builds on the proven performance of the OMNI® Surgical System...

More updates from Sight Sciences, Inc.